ORG Partners LLC bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,745 shares of the financial services provider’s stock, valued at approximately $239,000.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Crewe Advisors LLC lifted its stake in iShares Biotechnology ETF by 42.9% in the fourth quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock valued at $35,000 after buying an additional 78 shares during the period. Apexium Financial LP raised its position in shares of iShares Biotechnology ETF by 3.8% during the fourth quarter. Apexium Financial LP now owns 2,223 shares of the financial services provider’s stock worth $302,000 after purchasing an additional 82 shares during the period. Perkins Coie Trust Co raised its position in shares of iShares Biotechnology ETF by 0.3% during the second quarter. Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock worth $3,457,000 after purchasing an additional 83 shares during the period. Optimum Investment Advisors raised its position in shares of iShares Biotechnology ETF by 2.9% during the second quarter. Optimum Investment Advisors now owns 3,024 shares of the financial services provider’s stock worth $415,000 after purchasing an additional 85 shares during the period. Finally, Penbrook Management LLC raised its position in shares of iShares Biotechnology ETF by 2.3% during the first quarter. Penbrook Management LLC now owns 4,050 shares of the financial services provider’s stock worth $556,000 after purchasing an additional 90 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Down 0.5 %
Shares of NASDAQ IBB traded down $0.76 during mid-day trading on Wednesday, reaching $142.79. 750,142 shares of the company’s stock were exchanged, compared to its average volume of 1,599,161. The business has a fifty day simple moving average of $140.73 and a 200 day simple moving average of $136.60. iShares Biotechnology ETF has a twelve month low of $111.83 and a twelve month high of $150.17.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Brinker International’s Price Dip is an Appetizing Entry Point
- Using the MarketBeat Dividend Tax Calculator
- 3 Stocks That Could Beat the September Blues
- What is the Shanghai Stock Exchange Composite Index?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.